Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis.

Chua CYX, Jain P, Ballerini A, Bruno G, Hood RL, Gupte M, Gao S, Di Trani N, Susnjar A, Shelton K, Bushman LR, Folci M, Filgueira CS, Marzinke MA, Anderson PL, Hu M, Nehete P, Arduino RC, Sastry JK, Grattoni A.

J Control Release. 2018 Aug 6;286:315-325. doi: 10.1016/j.jconrel.2018.08.010. [Epub ahead of print]

PMID:
30092254
2.

In-capillary microextraction for direct mass spectrometry analysis of biological samples.

Ren Y, Zhang W, Lin Z, Bushman LR, Anderson PL, Ouyang Z.

Talanta. 2018 Nov 1;189:451-457. doi: 10.1016/j.talanta.2018.07.027. Epub 2018 Jul 11.

PMID:
30086946
3.

CYP2D6 Genotype Phenotype Discordance Due to Drug-Drug Interaction.

Monte AA, West K, McDaniel KT, Flaten HK, Saben J, Shelton S, Abdelmawla F, Bushman LR, Williamson K, Abbott D, Anderson PL.

Clin Pharmacol Ther. 2018 Jun 8. doi: 10.1002/cpt.1135. [Epub ahead of print]

PMID:
29882961
4.

Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.

MacBrayne CE, Marks KM, Fierer DS, Naggie S, Chung RT, Hughes MD, Kim AY, Peters MG, Brainard DM, Seifert SM, Castillo-Mancilla JR, Bushman LR, Anderson PL, Kiser JJ.

J Antimicrob Chemother. 2018 Aug 1;73(8):2112-2119. doi: 10.1093/jac/dky146.

PMID:
29746648
5.

Brief Report: Adherence Biomarker Measurements in Older and Younger HIV-Infected Adults Receiving Tenofovir-Based Therapy.

Seifert SM, Castillo-Mancilla JR, Erlandson K, Morrow M, Gandhi M, Kuncze K, Horng H, Zheng JH, Bushman LR, Kiser JJ, MaWhinney S, Anderson PL.

J Acquir Immune Defic Syndr. 2018 Mar 1;77(3):295-298. doi: 10.1097/QAI.0000000000001596.

PMID:
29189417
6.

Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.

Anderson PL, Liu AY, Castillo-Mancilla JR, Gardner EM, Seifert SM, McHugh C, Wagner T, Campbell K, Morrow M, Ibrahim M, Buchbinder S, Bushman LR, Kiser JJ, MaWhinney S.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01710-17. doi: 10.1128/AAC.01710-17. Print 2018 Jan.

7.

Small increase in dolutegravir trough, but equivalent total dolutegravir exposure with simeprevir in HIV/HCV seronegative volunteers.

MacBrayne CE, Castillo-Mancilla J, Burton JR Jr, MaWhinney S, Wagner CB, Micke K, Fey J, Huntley RT, Larson B, Bushman LR, Kiser JJ.

J Antimicrob Chemother. 2018 Jan 1;73(1):156-159. doi: 10.1093/jac/dkx344.

PMID:
29029135
8.

Cell-line dependent antiviral activity of sofosbuvir against Zika virus.

Mumtaz N, Jimmerson LC, Bushman LR, Kiser JJ, Aron G, Reusken CBEM, Koopmans MPG, van Kampen JJA.

Antiviral Res. 2017 Oct;146:161-163. doi: 10.1016/j.antiviral.2017.09.004. Epub 2017 Sep 11.

9.

Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.

Chen X, Seifert SM, Castillo-Mancilla JR, Bushman LR, Zheng JH, Kiser JJ, MaWhinney S, Anderson PL.

PLoS One. 2016 Nov 10;11(11):e0165505. doi: 10.1371/journal.pone.0165505. eCollection 2016.

10.

A LC-MS/MS Method for Quantifying Adenosine, Guanosine and Inosine Nucleotides in Human Cells.

Jimmerson LC, Bushman LR, Ray ML, Anderson PL, Kiser JJ.

Pharm Res. 2017 Jan;34(1):73-83. doi: 10.1007/s11095-016-2040-z. Epub 2016 Sep 15.

11.

Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.

Castillo-Mancilla J, Seifert S, Campbell K, Coleman S, McAllister K, Zheng JH, Gardner EM, Liu A, Glidden DV, Grant R, Hosek S, Wilson CM, Bushman LR, MaWhinney S, Anderson PL.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6692-6697. doi: 10.1128/AAC.01017-16. Print 2016 Nov.

12.

Development and validation of an LC-MS/MS quantitative method for endogenous deoxynucleoside triphosphates in cellular lysate.

Chen X, McAllister KJ, Klein B, Bushman LR, Anderson PL.

Biomed Chromatogr. 2017 Mar;31(3). doi: 10.1002/bmc.3820. Epub 2016 Sep 21.

13.

Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State.

Seifert SM, Chen X, Meditz AL, Castillo-Mancilla JR, Gardner EM, Predhomme JA, Clayton C, Austin G, Palmer BE, Zheng JH, Klein B, Kerr BJ, Guida LA, Rower C, Rower JE, Kiser JJ, Bushman LR, MaWhinney S, Anderson PL.

AIDS Res Hum Retroviruses. 2016 Oct/Nov;32(10-11):981-991. Epub 2016 Sep 19.

14.

Analysis of the Endogenous Deoxynucleoside Triphosphate Pool in HIV-Positive and -Negative Individuals Receiving Tenofovir-Emtricitabine.

Chen X, Castillo-Mancilla JR, Seifert SM, McAllister KB, Zheng JH, Bushman LR, MaWhinney S, Anderson PL.

Antimicrob Agents Chemother. 2016 Aug 22;60(9):5387-92. doi: 10.1128/AAC.01019-16. Print 2016 Sep.

15.

Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots.

Zheng JH, Rower C, McAllister K, Castillo-Mancilla J, Klein B, Meditz A, Guida LA, Kiser JJ, Bushman LR, Anderson PL.

J Pharm Biomed Anal. 2016 Apr 15;122:16-20. doi: 10.1016/j.jpba.2016.01.038. Epub 2016 Jan 21.

16.

Stability of Ribavirin for Inhalation Packaged in Syringes or Glass Vials when Stored Frozen, Refrigerated, and at Room Temperature.

Larson B, Bushman LR, Casciano ML, Oldland AR, Kiser JJ, Kiser TH.

Int J Pharm Compd. 2016 Nov-Dec;20(6):521-525.

PMID:
28339392
17.

Validation and Application of a Liquid Chromatography-Tandem Mass Spectrometry Method To Determine the Concentrations of Sofosbuvir Anabolites in Cells.

Rower JE, Jimmerson LC, Chen X, Zheng JH, Hodara A, Bushman LR, Anderson PL, Kiser JJ.

Antimicrob Agents Chemother. 2015 Dec;59(12):7671-9. doi: 10.1128/AAC.01693-15. Epub 2015 Sep 28.

18.

Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066).

Hendrix CW, Andrade A, Bumpus NN, Kashuba AD, Marzinke MA, Moore A, Anderson PL, Bushman LR, Fuchs EJ, Wiggins I, Radebaugh C, Prince HA, Bakshi RP, Wang R, Richardson P, Shieh E, McKinstry L, Li X, Donnell D, Elharrar V, Mayer KH, Patterson KB.

AIDS Res Hum Retroviruses. 2016 Jan;32(1):32-43. doi: 10.1089/AID.2015.0182. Epub 2015 Oct 15.

19.

Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir.

Dobard CW, Taylor A, Sharma S, Anderson PL, Bushman LR, Chuong D, Pau CP, Hanson D, Wang L, Garcia-Lerma JG, McGowan I, Rohan L, Heneine W.

J Infect Dis. 2015 Dec 15;212(12):1988-95. doi: 10.1093/infdis/jiv334. Epub 2015 Jun 12.

20.

Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin.

Rower JE, Meissner EG, Jimmerson LC, Osinusi A, Sims Z, Petersen T, Bushman LR, Wolfe P, McHutchison JG, Kottilil S, Kiser JJ.

J Antimicrob Chemother. 2015 Aug;70(8):2322-9. doi: 10.1093/jac/dkv122. Epub 2015 May 13.

21.

Reduced immune activation during tenofovir-emtricitabine therapy in HIV-negative individuals.

Castillo-Mancilla JR, Meditz A, Wilson C, Zheng JH, Palmer BE, Lee EJ, Gardner EM, Seifert S, Kerr B, Bushman LR, MaWhinney S, Anderson PL.

J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):495-501. doi: 10.1097/QAI.0000000000000529.

22.

Measurement of intracellular ribavirin mono-, di- and triphosphate using solid phase extraction and LC-MS/MS quantification.

Jimmerson LC, Ray ML, Bushman LR, Anderson PL, Klein B, Rower JE, Zheng JH, Kiser JJ.

J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Jan 26;978-979:163-72. doi: 10.1016/j.jchromb.2014.11.032. Epub 2014 Dec 17.

23.

Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men.

Seifert SM, Glidden DV, Meditz AL, Castillo-Mancilla JR, Gardner EM, Predhomme JA, Rower C, Klein B, Kerr BJ, Guida LA, Zheng JH, Bushman LR, Anderson PL.

Clin Infect Dis. 2015 Mar 1;60(5):804-10. doi: 10.1093/cid/ciu916. Epub 2014 Nov 18. Erratum in: Clin Infect Dis. 2015 Jul 1;61(1):143.

24.

Short communication: Tenofovir diphosphate in dried blood spots as an objective measure of adherence in HIV-infected women.

Castillo-Mancilla JR, Searls K, Caraway P, Zheng JH, Gardner EM, Predhomme J, Bushman LR, Anderson PL, Meditz AL.

AIDS Res Hum Retroviruses. 2015 Apr;31(4):428-32. doi: 10.1089/AID.2014.0229. Epub 2014 Nov 20.

25.

Intrahepatic antiviral quantification in a patient undergoing orthotopic cadaveric liver transplantation.

Moorehead KJ, Burton JR Jr, Everson GT, Zheng JH, Kerr BJ, Bushman LR, Wang M, Ju C, Nydam T, Kiser JJ.

J Antimicrob Chemother. 2015 Jan;70(1):315-7. doi: 10.1093/jac/dku334. Epub 2014 Sep 11. No abstract available.

26.

Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission.

Anderson PL, Glidden DV, Bushman LR, Heneine W, García-Lerma JG.

J Antimicrob Chemother. 2014 Sep;69(9):2470-6. doi: 10.1093/jac/dku162. Epub 2014 May 26.

27.

Validation of a sensitive LC/MS/MS method for the determination of telaprevir and its R-isomer in human plasma.

Chen X, Bushman LR, McAllister KJ, Anderson PL, Kiser JJ.

Biomed Chromatogr. 2014 Dec;28(12):1714-21. doi: 10.1002/bmc.3211. Epub 2014 Apr 24.

PMID:
24760592
28.

Development and validation of a dried blood spot assay for the quantification of ribavirin using liquid chromatography coupled to mass spectrometry.

Jimmerson LC, Zheng JH, Bushman LR, MacBrayne CE, Anderson PL, Kiser JJ.

J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jan 1;944:18-24. doi: 10.1016/j.jchromb.2013.10.035. Epub 2013 Oct 31.

29.

Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers.

Hammond KP, Wolfe P, Burton JR Jr, Predhomme JA, Ellis CM, Ray ML, Bushman LR, Kiser JJ.

J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):67-73. doi: 10.1097/QAI.0b013e318275da93.

PMID:
23075915
30.

Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.

Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, McMahan V, Bushman LR, Casapía M, Montoya-Herrera O, Veloso VG, Mayer KH, Chariyalertsak S, Schechter M, Bekker LG, Kallás EG, Grant RM; iPrEx Study Team.

Sci Transl Med. 2012 Sep 12;4(151):151ra125.

31.

Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.

Castillo-Mancilla JR, Zheng JH, Rower JE, Meditz A, Gardner EM, Predhomme J, Fernandez C, Langness J, Kiser JJ, Bushman LR, Anderson PL.

AIDS Res Hum Retroviruses. 2013 Feb;29(2):384-90. doi: 10.1089/AID.2012.0089. Epub 2012 Oct 10.

32.

Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone.

Aquilante CL, Kosmiski LA, Bourne DW, Bushman LR, Daily EB, Hammond KP, Hopley CW, Kadam RS, Kanack AT, Kompella UB, Le M, Predhomme JA, Rower JE, Sidhom MS.

Br J Clin Pharmacol. 2013 Jan;75(1):217-26. doi: 10.1111/j.1365-2125.2012.04343.x.

33.

Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine.

Rower JE, Meditz A, Gardner EM, Lichtenstein K, Predhomme J, Bushman LR, Klein B, Zheng JH, Mawhinney S, Anderson PL.

Antimicrob Agents Chemother. 2012 Jun;56(6):3011-9. doi: 10.1128/AAC.06337-11. Epub 2012 Mar 5.

34.
35.

Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection.

Bushman LR, Kiser JJ, Rower JE, Klein B, Zheng JH, Ray ML, Anderson PL.

J Pharm Biomed Anal. 2011 Sep 10;56(2):390-401. doi: 10.1016/j.jpba.2011.05.039. Epub 2011 Jun 6.

36.

Validation of a sensitive LC/MS/MS method for the determination of zidovudine and lamivudine in human plasma.

Rower JE, Klein B, Bushman LR, Anderson PL.

Biomed Chromatogr. 2012 Jan;26(1):12-20. doi: 10.1002/bmc.1617. Epub 2011 Apr 4.

37.

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallás EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV; iPrEx Study Team.

N Engl J Med. 2010 Dec 30;363(27):2587-99. doi: 10.1056/NEJMoa1011205. Epub 2010 Nov 23.

38.

Validation of an LC/MS method for the determination of gemfibrozil in human plasma and its application to a pharmacokinetic study.

Rower JE, Bushman LR, Hammond KP, Kadam RS, Aquilante CL.

Biomed Chromatogr. 2010 Dec;24(12):1300-8. doi: 10.1002/bmc.1440.

40.

Teriflunomide encourages cytostatic and apoptotic effects in premalignant and malignant cutaneous keratinocytes.

Hail N Jr, Chen P, Rower J, Bushman LR.

Apoptosis. 2010 Oct;15(10):1234-46. doi: 10.1007/s10495-010-0518-4.

PMID:
20544286
41.

Dihydroorotate dehydrogenase is required for N-(4-hydroxyphenyl)retinamide-induced reactive oxygen species production and apoptosis.

Hail N Jr, Chen P, Kepa JJ, Bushman LR, Shearn C.

Free Radic Biol Med. 2010 Jul 1;49(1):109-16. doi: 10.1016/j.freeradbiomed.2010.04.006. Epub 2010 Apr 24.

42.

Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors.

Anderson PL, Aquilante CL, Gardner EM, Predhomme J, McDaneld P, Bushman LR, Zheng JH, Ray M, MaWhinney S.

J Antimicrob Chemother. 2009 Nov;64(5):1071-9. doi: 10.1093/jac/dkp317. Epub 2009 Aug 26.

43.

Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers.

Aquilante CL, Bushman LR, Knutsen SD, Burt LE, Rome LC, Kosmiski LA.

Hum Genomics. 2008 Sep;3(1):7-16.

44.

Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults.

Anderson PL, Zheng JH, King T, Bushman LR, Predhomme J, Meditz A, Gerber J, Fletcher CV.

AIDS. 2007 Sep 12;21(14):1849-54.

PMID:
17721092
45.

The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.

Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, King TM, Delahunty T, Bushman LR, Fletcher CV.

Clin Pharmacol Ther. 2008 Feb;83(2):265-72. Epub 2007 Jun 27.

PMID:
17597712
46.

Atazanavir-containing renal calculi in an HIV-infected patient.

Anderson PL, Lichtenstein KA, Gerig NE, Kiser JJ, Bushman LR.

AIDS. 2007 May 11;21(8):1060-2. No abstract available.

PMID:
17457108
47.

Stability of zidovudine with oxytocin in a simulated Y-site injection.

Anderson PL, Miller S, Bushman LR.

Am J Health Syst Pharm. 2004 Feb 15;61(4):394-6. No abstract available.

PMID:
15011769
48.

Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons.

Fletcher CV, Kawle SP, Kakuda TN, Anderson PL, Weller D, Bushman LR, Brundage RC, Remmel RP.

AIDS. 2000 Sep 29;14(14):2137-44.

PMID:
11061655

Supplemental Content

Loading ...
Support Center